The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Breast Cancer Res Treat. 2015 Feb;149(3):607-18. doi: 10.1007/s10549-015-3270-1. Epub 2015 Jan 28.
Breast Cancer Res Treat. 2015.
PMID: 25627551
Free PMC article.